Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
Share Facebook Twitter LinkedIn Pinterest Email Boise State’s A’Marion McCoy makes interception and returns it to endzone, extending lead over UNLV
